BB Biotech AG lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,370,538 shares of the biopharmaceutical company’s stock after purchasing an additional 230,000 shares during the quarter. Alnylam Pharmaceuticals accounts for 3.2% of BB Biotech AG’s holdings, making the stock its 12th biggest holding. BB Biotech AG owned approximately 1.36% of Alnylam Pharmaceuticals worth $119,949,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Xact Kapitalforvaltning AB lifted its position in shares of Alnylam Pharmaceuticals by 3.1% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 15,929 shares of the biopharmaceutical company’s stock worth $1,569,000 after buying an additional 486 shares during the last quarter. BTG Pactual Global Asset Management Ltd lifted its position in shares of Alnylam Pharmaceuticals by 17.3% during the 2nd quarter. BTG Pactual Global Asset Management Ltd now owns 4,410 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 652 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in shares of Alnylam Pharmaceuticals by 7.1% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 12,070 shares of the biopharmaceutical company’s stock worth $1,056,000 after buying an additional 800 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of Alnylam Pharmaceuticals by 9.7% during the 3rd quarter. Toronto Dominion Bank now owns 9,827 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 869 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 98.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 960 shares during the last quarter. 90.63% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals stock opened at $72.68 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.96 and a current ratio of 11.05. Alnylam Pharmaceuticals, Inc. has a 12 month low of $63.57 and a 12 month high of $153.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.02) by ($0.41). The firm had revenue of $2.07 million during the quarter, compared to the consensus estimate of $22.66 million. Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. Alnylam Pharmaceuticals’s revenue for the quarter was down 87.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.34) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.65 EPS for the current year.

Several brokerages recently weighed in on ALNY. Stifel Nicolaus upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $95.00 to $125.00 in a research report on Monday, August 6th. BidaskClub downgraded Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 10th. Needham & Company LLC restated a “buy” rating and set a $152.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, August 13th. Jefferies Financial Group restated a “buy” rating and set a $149.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, August 6th. Finally, ValuEngine downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 7th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $142.94.

In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,916 shares in the company, valued at $229,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “BB Biotech AG Has $119.95 Million Stake in Alnylam Pharmaceuticals, Inc. (ALNY)” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2018/11/22/bb-biotech-ag-has-119-95-million-stake-in-alnylam-pharmaceuticals-inc-alny.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

See Also: Quiet Period

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.